UBS lowered the firm’s price target on Cabot (CBT) to $83 from $93 and keeps a Neutral rating on the shares. The firm sees another challenging earnings cycle, with “largely ok” downstream earnings, while upstream/commodity earnings will be impacted by higher costs and likely weaker end of quarter demand, the analyst tells investors in a research note. UBS sees earnings misses to drive stocks down vs. provide relief.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBT: